secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2023-08-28T23:59:59+00:00
Accession:  0001493152-23-030356
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte's VitaGraft Kidney test receives Medicare coverage decision from Palmetto GBA
--------------------------------------------------------------------------------

- Palmetto GBA, a Medicare Administrative Contractor, issued final LCD for VitaGraft Kidney test.
- Test meets coverage criteria under MolDX: Molecular Testing for Solid Organ Allograft Rejection (L38568).
- Decision could enable Medicare reimbursement for Oncocyte's transplant rejection test.
- Coverage applies to beneficiaries under Palmetto GBA's jurisdiction.
- Oncocyte announced the decision in an August 28, 2023 press release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223030356/0001493152-23-030356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223030356/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-030356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer